ibodutant candidate drug irritable bowel syndrome diarrhea developed menarini group march underwent multicentre double blind efficacy clinical study ibodutant selectively blocks tachykinin receptor blockade practically complete nanomolar concentrations phase trial europe trial completed may positive results phase study terminated low response negative results study drug article relating nervous system stub help wikipedia expanding httpsenwikipediaorgwikiibodutant